Shigeki Sato
Kanazawa, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.
Journal: Oncogene
Published: October 29, 2025
Longitudinal Trend in Hospital-Wide Syphilis Testing and Clinical Characteristics of Syphilis Requiring Treatment.
Journal: Pathogens (Basel, Switzerland)
Published: August 12, 2025
MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity.
Journal: Cancer science
Published: July 31, 2025
Limited SUMOylation inhibitor administration enhances eradication of Burkitt's lymphoma with CD19 CAR-T therapy.
Journal: Signal transduction and targeted therapy
Published: May 09, 2025
Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer.
Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 06, 2025
Case Report: Medullary carcinoma of the pancreas with MLH1 promoter hypermethylation, induced deficient mismatch repair, successfully treated with an immune checkpoint inhibitor.
Journal: Frontiers in oncology
Published: December 24, 2024
Development and Characterization of a Patient-Derived KIF5B-RET Fusion Lung Adenocarcinoma Cell Line for Subcutaneous and Central Nervous System Tumor Models in Immunodeficient Mice.
Journal: JTO clinical and research reports
Published: December 19, 2024
Analysis of Methylation of Tumor-suppressive miRNAs and KRAS/TP53 Mutations in Pancreatic Juice.
Journal: Anticancer research
Published: October 15, 2024
Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case Reports.
Journal: Internal medicine (Tokyo, Japan)
Published: September 04, 2024
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers.
Journal: Experimental hematology & oncology
Published: June 24, 2024
Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: A case study and implications for precision oncology.
Journal: Cancer science
Published: March 19, 2024
Last Updated: 09/26/2026